Precision Biosciences Inc (NASDAQ: DTIL): Can The Stock Still Lose Despite An -65.53% YTD Loss?
Precision Biosciences Inc (NASDAQ:DTIL) saw a decrease in its traded shares during the latest session, with the company’s beta value hitting 1.50. The stock’s price currently stands at $0.41, implying a decrease of -3.21% or -$0.01 in intraday trading. While the stock is -263.41% down from its 52-week high of $1.49, it has still made an impressive 31.71% recovery since its 52-week low of $0.28. The company’s valuation is currently $48.79M, with an average intraday trading volume of 0.84 million shares over the past 10 days and 927.48K shares over the past 3 months.
Analysts have given Precision Biosciences Inc (DTIL) a consensus recommendation of Overweight, with a mean rating of 1.50. Out of 4 analysts looking at the stock, 0 rate it as a Sell, 1 advises holding, and 3 recommend it as a Buy. Estimates project the company’s current-quarter earnings per share at -$0.07.
Following a -3.21% decline in the latest session, Precision Biosciences Inc (DTIL) has experienced negative performance over the past five days. The stock reached a weekly high of $0.4695 on November 22, 2023, but dropped -3.21% during intraday trading. In the last 5 days, the stock has shown a price performance of 7.33% and a 30-day performance of 43.48%. However, the year-to-date price performance is still at a considerable loss of -65.53%. Short interest in Precision Biosciences Inc (NASDAQ:DTIL) currently stands at 0.61 million shares, with a 0.73 days time to cover.
Wall Street analysts suggest a consensus price target of $2.63 for Precision Biosciences Inc (DTIL), indicating a potential increase of 84.41% from the stock’s recent value. The target low and high prices are estimated at $2.00 and $3.00, respectively. Presently, DTIL is trading -631.71% below the suggested target high and -387.8% from its likely low.
In comparison to its industry peers, Precision Biosciences Inc has outperformed competitors. The company’s shares are -43.99% down over the last 6 months, with a year-to-date growth rate of 77.17% compared to the industry average of 14.90%. Revenue forecasts predict a 73.10% growth rate for the current quarter, followed by a 52.20% increase in the next quarter. Overall, analysts project a 112.40% revenue growth compared to the previous financial year.
For the current quarter, analysts estimate Precision Biosciences Inc’s revenue to be $12.48 million. Looking ahead to the quarter ending March 2024, analysts expect revenue to grow to $8.82 million.
Precision Biosciences Inc’s next earnings report is scheduled for November 7. It’s important to consider that the dividend yield ratio is just one indicator, and investors should also analyze other fundamental and operational aspects of the company. Precision Biosciences Inc currently has a forward dividend ratio of 0, and the share yield has been steadily rising over the past year at 0.00%. The average dividend yield for the company over the past 5 years is 0.00%.
In terms of ownership, Precision Biosciences Inc insiders hold 14.90% of the total outstanding shares, while institutional holders own 43.77% of the shares, representing 51.43% of the float. Great Point Partners LLC is the leading institution holding shares in the company, owning over 7.47 million shares (6.49% of shares) valued at roughly $3.93 million as of June 29, 2023.
The second-largest institutional holder is Capital World Investors, with 6.72 million shares, or about 5.84% of shares outstanding. These shares were worth $3.53 million based on the market price on June 29, 2023.
The top two mutual funds with the largest holdings of Precision Biosciences Inc (DTIL) shares are Smallcap World Fund and Vanguard Total Stock Market Index Fund. As of June 29, 2023, Smallcap World Fund holds roughly 6.72 million shares, accounting for just over 5.84% of the total shares, with a market valuation of $3.53 million. On the same date, Vanguard Total Stock Market Index Fund holds slightly less with 2.44 million shares, or 2.12% of the shares, valued at approximately $1.28 million.
Overall, while Precision Biosciences Inc (NASDAQ: DTIL) has faced a significant YTD loss of -65.53%, recent performance suggests potential for recovery. Analysts project growth in revenue and recommend the stock as a Buy. Investors should carefully consider the company’s fundamental and operational aspects before making investment decisions.
Note: The information provided does not constitute financial advice or recommendations. Always conduct thorough research and consult with a professional financial advisor before making investment decisions.
*All data and numbers mentioned in the article are accurate at the time of writing.
